Organization
Cedars-Sinai Medical Center
46 clinical trials
62 abstracts
1 poster
Clinical trial
The Role of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas LesionsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Prospective Study Comparing Total Intravenous Anesthesia With Propofol and Remifentanil vs. Propofol and Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion and InstrumentationStatus: Recruiting, Estimated PCD: 2027-12-01
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,
Abstract
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.Org: Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Department of clinical and molecular medicine, Faculty of Medicine and Health Sciences,
Abstract
Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Massachusetts General Hospital, Aflac Cancer Center/Children's Healthcare of Atlanta, Children's Hospital & Clinics Minnesota, Cedars-Sinai Medical Center,
Abstract
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,
Abstract
Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC).Org: Cedars-Sinai Medical Center, City of Hope National Medical Center, Washington University in St. Louis, Allegheny Health Network Cancer Institute, Tempus AI,
Abstract
Evaluating the feasibility of a Mobile Audio Companion (Elly) to reduce anxiety and to improve patient-reported outcomes among patients with cancer.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Clinical trial
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young WomenStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic PancreatitisStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Abstract
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, Department of Urology and Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland, Instituto Valenciano de Oncologia, Valencia, Spain, Astellas Pharma Inc., Northbrook, IL, Pfizer Inc., New York, NY,
Clinical trial
A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitisStatus: Recruiting, Estimated PCD: 2025-03-01
Abstract
Site research infrastructure and institutional performance: A report from the Voting Body of the Children’s Oncology Group (COG).Org: University of Oklahoma Health Sciences Center, Georgetown University Lombardi Comprehensive Cancer Center, St. Luke's Cancer Institute, Children's Hospital Colorado, Aurora, CO, University of California Davis, Sacramento, CA,
Abstract
Neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC) with germline DNA damage repair (DDR) mutations: A dual institution retrospective study.Org: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
First-in-human autologous CAR-T for metastatic breast cancers to target growth factor receptor MUC1*.Org: Minerva Biotechnologies, City of Hope Comprehensive Cancer Center, Cedars-Sinai Medical Center, University of Washington and Fred Hutchinson Cancer Research Centre, City of Hope National Medical Center,
Abstract
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.Org: Foundation Medicine, Inc., Cambridge, MA, Cedars-Sinai Medical Center, SUNY Upstate Medical University, University of California, San Diego Health,
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
Trends of demographic and clinical traits of young patients with breast cancer from the National Cancer Database: Disproportionate effect on underrepresented underserved populations.Org: Cedars-Sinai Medical Center,
Abstract
A qualitative exploration of perceptions of the value of wearable activity monitors among prostate cancer survivors undergoing androgen deprivation therapy.Org: Cedars-Sinai Medical Center, Durham VA Medical Center,
Abstract
Pancreatic-enzyme replacement therapy with pancrelipase plus chemotherapy for patients with pancreatic adenocarcinoma with cachexia and exocrine pancreatic insufficiency (PANCAX-3).Org: Cedars-Sinai Medical Center, Cedars Sinai Medical Center, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,
Abstract
First- and second-line biomarker utilization in non-small cell lung cancer.Org: Cedars-Sinai Medical Center, Los Angeles Medical Center, CanSino Biologics,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.Org: Yale New Haven Hospital, Yale Cancer Center, Stanford Hospital and Clinics, Campus Bio Medico University of Rome, MedStar Health/Georgetown University Hospital,
Clinical trial
Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 StudyStatus: Completed, Estimated PCD: 2023-01-28
Clinical trial
Prospective Randomized Controlled Trial of an Enhanced Recovery Protocol for Anorectal SurgeryStatus: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Phase I/II, Double-Blind, Placebo-Controlled Study: Assessing Safety and Efficacy of Preoperative Renal Allograft Infusions of C1 Inhibitor (Berinert®) (Human) (C1INH) vs. Placebo Administration in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI)Status: Active (not recruiting), Estimated PCD: 2022-07-31
Clinical trial
The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's DiseaseStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up StudyStatus: , Estimated PCD: 2025-12-30
Clinical trial
Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH StudyStatus: Terminated, Estimated PCD: 2021-12-07
Clinical trial
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up StudyStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-07-15
Clinical trial
A Prospective Study Comparing Total Intravenous Anesthesia With Propofol and Remifentanil vs. Propofol and Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion and InstrumentationStatus: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip ArthroscopyStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
IIT2019-20-Zumsteg-HPVOPC: Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal CancerStatus: Recruiting, Estimated PCD: 2026-12-15
Clinical trial
A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 InfectionStatus: Completed, Estimated PCD: 2020-09-30
Clinical trial
Intraoperative Ketamine and Methadone for Laminectomy: Effect on Recovery, Postoperative Pain, and Opioid RequirementsStatus: Terminated, Estimated PCD: 2023-01-01
Clinical trial
A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF (APOTHECARY AF Study)Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart FailureStatus: Completed, Estimated PCD: 2021-10-25
Clinical trial
Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral SclerosisStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Correlates and Control of Blood Pressure VariabilityStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Use of Allograft Adipose Matrix for Small Joint Arthritis of the HandStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Prospective, Pilot Trial to Compare the Efficacy of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release on Suppression of Donor-Specific Antibodies in HLA Sensitized Kidney Transplant RecipientsStatus: Active (not recruiting), Estimated PCD: 2023-07-21
Clinical trial
Effects of Anesthetic Technique on Natural Killer Cell Population and CytotoxicityStatus: , Estimated PCD: 2025-12-01
Clinical trial
Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) LymphocytesStatus: Not yet recruiting, Estimated PCD: 2028-02-29
Clinical trial
Regress-HFpEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCsStatus: Completed, Estimated PCD: 2023-04-28
Clinical trial
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Dysfunction With Multimodality Imaging and Its TrEatment With AnticoagulationStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single Center Open-Label Prospective Study Of Oral Tofacitinib In Patients With Chronic PouchitisStatus: Terminated, Estimated PCD: 2022-12-01
Clinical trial
Do Oral Contraceptives Protect Against Anterior Cruciate Ligament Injuries in Female AthletesStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming SurgeriesStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's DiseaseStatus: Completed, Estimated PCD: 2022-08-03
Clinical trial
Whole-Heart Myocardial Blood Flow Quantification Using Magnetic Resonance ImagingStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis PigmentosaStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Using Mirabegron to Increase Blood Pressure in Patients With Postural Orthostatic Tachycardia SyndromeStatus: Recruiting, Estimated PCD: 2025-11-21
Clinical trial
A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA TrialStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell GrowthStatus: Completed, Estimated PCD: 2019-02-28
Clinical trial
A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant RecipientsStatus: , Estimated PCD: 2024-10-31
Clinical trial
Standard vs. Lower Pressure Pneumoperitoneum in Laparoscopic Gynecologic Surgery: A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALLStatus: Active (not recruiting), Estimated PCD: 2023-03-27
Abstract
A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.Org: Cedars-Sinai Medical Center, University of Iowa Hospitals and Clinics, NRG Oncology, University of Texas MD Anderson Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute,
Abstract
High-risk constitutional MLH1 methylation as a cause of early-onset colorectal and endometrial cancers displaying mismatch repair deficiency and MLH1 methylation.Org: Cedars-Sinai Medical Center, Stanford University School of Medicine, Stanford Health Care, University of New Mexico Comprehensive Cancer Center, Inova Schar Cancer Institute,
Abstract
The ketogenic diet plus standard of care for adults with recently diagnosed glioblastoma: Results from a phase 1 trial.Org: Cedars-Sinai Comprehensive Cancer Center, Cedars-Sinai Medical Center, Cedars-Sinai Cancer, Massachusetts General Hospital, University of California Irvine,
Abstract
Racial differences in the utilization of MRI-guided biopsy before prostate cancer diagnosis.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sidney Kimmel Medical College of Thomas Jefferson University, Sidney Kimmel Cancer Center at Jefferson Health, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA,
Abstract
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center Medical, Cedars-Sinai Cancer, Cedars-Sinai Cancer Beverly Hills, Cedars-Sinai Cancer Tarzana,
Abstract
Assessing racial differences in time to treatment escalation following androgen-deprivation therapy among veterans with prostate cancer.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Health Care System, Institute for Medical Research,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.Org: USF Health Morsani College of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, MSKCC,
Abstract
Neurocognitive function outcomes in NRG/RTOG 0534, the SPPORT trial.Org: MD Anderson Cancer Center, University of Chicago, University of Miami Health System, Tom Baker Cancer Centre, Emory University, Atlanta, GA, USA,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.Org: University of Texas Southwestern Medical Center, Clion - CAM Group, Cedars-Sinai Medical Center, Cancer Care Assoc-TMPN, Cancer Care Associates of York,
Abstract
Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Duke University Medical Center, NRG Oncology, University of Iowa Hospitals and Clinics,
Abstract
Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).Org: Cedars-Sinai Medical Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Johns Hopkins University Bloomberg School of Public Health, Verastem, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Perthera, Oregon Health & Science University, Pancreatic Cancer Action Network, Cedars-Sinai Medical Center,
Abstract
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.Org: Veracyte, Inc., South Australian Immunogenomics Cancer Institute, Institute of Cancer Research, Medical College of Wisconsin, Cedars-Sinai Medical Center,
Abstract
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Brigham and Women's Hospital/Massachusetts General Hospital, Princess Margaret Cancer Centre, Stanford Cancer Institute, Mayo Clinic,
Abstract
A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.Org: Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Huntsman Cancer Institute at the University of Utah, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,
Abstract
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.Org: Thompson Cancer Survival Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, City of Hope Comprehensive Cancer Center, Earle A Chiles Research Institute, Cedars-Sinai Cancer,
Abstract
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.Org: Memorial Sloan Kettering Cancer Center, Merck & Co, Inc., Linnaeus Therapeutics, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Pancreatic cancer associated ascites: Risk factors, outcomes, and management.Org: California University of Science and Medicine, Cedars-Sinai Medical Center,
Abstract
Radiogenomics of muscle invasive bladder cancer.Org: Cedars-Sinai Medical Center, Cedars-Sinai Comprehensive Cancer Center,
Abstract
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).Org: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center,
Abstract
Plasma-based methylated SEPTIN9 circulating tumor DNA to predict progression-free and overall survival in metastatic colorectal cancer.Org: Cedars-Sinai Medical Center,
Abstract
Characterization of pre-malignant lesions in patients with pediatric neurofibromatosis type 1 using a novel whole-body magnetic resonance imaging technique.Org: Cedars-Sinai Medical Center Medical Pediatric Hematology/Oncology, Cedars-Sinai Medical Center, Cedars-Sinai Biomedical Imaging Research Institute, Cedars-Sinai Cancer,
Abstract
Identification of a novel class of early exon ALK rearrangements across two pan tumor sequencing databases.Org: Cedars-Sinai Medical Center, Los Angeles Medical Center, CanSino Biologics, Tempus Labs, Inc., Chicago, IL,
Abstract
Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management.Org: Project Ronin, Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, Cedars-Sinai Medical Center,
Abstract
Dissecting the tumor microenvironment of papillary thyroid carcinomas in primary tumor and metastatic lymph nodes at single-cell resolution.Org: Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
Luminal and basal subtyping of circulating tumor cells and influence on outcomes in patients with metastatic castration-resistant prostate cancer.Org: Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Division of Cancer Systems Biology, Department of Surgery, Brigham and Women's Hospital, Boston, MA, California NanoSystems Institute, University of California,
Abstract
Impact of hospital volume and margin status on survival following radical hysterectomy: An expanded NCDB study.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, University of South Florida Morsani College of Medicine, Cedars-Sinai Medical Center, USF Health Morsani College of Medicine,
Abstract
Association of intermediates of bioenergetic pathways and plasma metabolomics with colorectal cancer (CRC): Diagnosis, stage, and survival.Org: Cedars-Sinai Medical Center, UCLA Metabolomics Center, Olive View-UCLA Medical Center, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine,
Abstract
Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.Org: Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Formerly of Astellas Pharma Inc., Current affiliation, Pfizer Inc., Astellas Pharma Inc.,
Abstract
CDH12 and the development of the neuronal subtype in MIBC.Org: Cedars-Sinai Medical Center, Cedars-Sinai Comprehensive Cancer Center, Cedars-Sinai Medical Center Medical Genetics Prenatal Diagnosis Center, Samuel Oschin Comprehensive Cancer Institute,
Abstract
The influence of grade on mortality risk in salivary gland malignancy.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center Medical Genetics Prenatal Diagnosis Center, Cedars Sinai Medical Center, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).Org: Abramson Cancer Center at the University of Pennsylvania, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Medical College of Wisconsin, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center,
Abstract
The impact of ImmunoPrecision in small bowel adenocarcinoma.Org: Cedars-Sinai The Angeles Clinic and Research Institute, University of New Mexico Comprehensive Cancer Center, Texas Oncology-Austin Lakeway, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Masonic Cancer Center, University of Minnesota, Minneapolis, MN,
Abstract
Non-hematopoietic cell transplant-related veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in solid tumor and hematologic malignancies: A systematic review.Org: Xcenda LLC, Jazz Pharmaceuticals, Cedars-Sinai Medical Center,
Abstract
AN ESTIMATE OF INDIRECT COST SAVINGS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: SUB-ANALYSIS OF THE PREMIER HEALTH OUTCOMES COMPANION STUDYOrg: Abbott, Cedars-Sinai Medical Center,
Abstract
ANTI-FLAGELLIN ANTIBODIES IN ANKYLOSING SPONDYLITIS (AS) IMPLICATE SUBCLINICAL BOWEL INFLAMMATION AND DIFFERENTIATE AS FROM MECHANICAL BACK PAIN PATIENTS. Org: Toronto Western Hospital, University Health Network, Toronto, Cedars-Sinai Medical Center,
Abstract
A SYSTEMATIC ANALYSIS OF CIRCULATING B CELL POPULATIONS IN HEALTHY AND SLE SUBJECTSOrg: Clinical Immunology Unit, Dept. of Medicine, Department of Pathology, Rogaland Central Hospital, Stavanger, Norway, Amgen, Thousand Oaks, Cedars-Sinai Medical Center, Los Angeles Medical Center,
Abstract
ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: CONTINUED EFFICACY UP TO 4 YEARS IN OPEN-LABEL TRIALSOrg: Denver Arthritis Clinic, Cedars-Sinai Medical Center, UCLA Department of Medicine, Center for Innovative Therapy, UCSD, San Diego, CA,
Abstract
BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIALOrg: Eli Lilly and Company, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States, Cedars-Sinai Medical Center, University California at Los Angeles,